Human non-small cell lung cancers (NSCLCs) with activating mutations in EGFR frequently respond to treatment with EGFRtargeted tyrosine kinase inhibitors (TKIs), such as erlotinib, but responses are not durable, as tumors acquire resistance. Secondary mutations in EGFR (such as T790M) or upregulation of the MET kinase are found in over 50% of resistant tumors. Here, we report increased activation of AXL and evidence for epithelial-to-mesenchymal transition (EMT) in multiple in vitro and in vivo EGFR-mutant lung cancer models with acquired resistance to erlotinib in the absence of the EGFR p.Thr790Met alteration or MET activation. Genetic or pharmacological inhibition of AXL restored sensitivity to erlotinib in these tumor models. Increased expression of AXL and, in some cases, of its ligand GAS6 was found in EGFR-mutant lung cancers obtained from individuals with acquired resistance to TKIs. These data identify AXL as a promising therapeutic target whose inhibition could prevent or overcome acquired resistance to EGFR TKIs in individuals with EGFR-mutant lung cancer.
A r t i c l e s Non-small cell lung cancer has served as a model for genotypedirected, targeted cancer therapy. Individuals with NSCLC whose tumors harbor activating mutations in EGFR (encoding epidermal growth factor receptor) that affect the kinase domain often initially respond to treatment with an EGFR-targeted TKI such as erlotinib [1] [2] [3] [4] . However, acquired resistance to EGFR TKI treatment invariably occurs 5, 6 , and there is no effective therapy for individuals who develop such resistance. Work by our group and others has shown that resistance to EGFR TKI treatment can occur through the introduction of a secondary mutation in EGFR (encoding a p.Thr790Met alteration), increased expression of the MET kinase and activation of the nuclear factor (NF)-κB pathway [7] [8] [9] [10] [11] [12] . The mechanisms underlying acquired resistance to EGFR TKI treatment are unknown in over 40% of individuals with EGFR-mutant NSCLC.
Recent studies indicate that multiple resistance mechanisms may operate within an individual tumor to promote acquired resistance to EGFR TKIs in persons with NSCLC. For example, the EGFR p.Thr790Met resistance-conferring alteration and activation of MET can co-occur in some EGFR-mutant NSCLCs with acquired resistance to EGFR TKI treatment 12, 13 . Furthermore, recent evidence suggests that the acquisition of EGFR TKI resistance in EGFR-mutant NSCLCs may be associated not only with genotypic alterations but also with histological changes that occur during adaptation to therapy 14 .
By studying human EGFR-mutant NSCLC tumor models and clinical specimens, our aim was to (i) identify novel mechanisms of acquired resistance to EGFR TKI treatment and (ii) further clarify the extent to which distinct and coexistent genotypic and Activation of the AXL kinase causes resistance to EGFRtargeted therapy in lung cancer A r t i c l e s histological changes promote the acquisition of resistance to EGFR TKI treatment in individuals with NSCLC.
RESULTS

AXL promotes resistance in vivo and in vitro
To identify novel mechanisms of acquired resistance to EGFR-targeted TKI treatment, the three groups participating in the current study independently established new in vivo and in vitro (n = 5) models of acquired resistance to the EGFR TKI erlotinib, using human NSCLC HCC827 cells with deletion of exon 19 of EGFR (p.Glu746_Ala750del). HCC827 cells are initially sensitive to erlotinib treatment (in vitro half-maximal inhibitory concentration (IC 50 ) of ~5 nM), and we and others have used them to develop in vitro models of acquired resistance to EGFR TKIs in studies that have led to the identification of clinically relevant mechanisms of EGFR TKI resistance 10, 11 . To establish an in vivo model, cohorts of five mice with established HCC827derived tumors (two tumors per mouse) were treated with vehicle alone or with four increasing doses of erlotinib (from 6.25 to 50 mg/ kg/d) over ~5 months to derive erlotinib-resistant tumors. Erlotinib treatment of HCC827-derived xenograft tumors (ten tumors per dose, daily treatment) resulted in an initial dose-dependent decrease in tumor volume and the subsequent development of acquired resistance (>25% regrowth from maximal reduction) after 6-10 weeks of treatment in each tumor ( Fig. 1a and Table 1 ). Sequencing of EGFR in each erlotinib-resistant tumor showed that none harbored the EGFR mutation encoding p.Thr790Met nor other secondary alterations associated with erlotinib resistance (p.Asp761Tyr, p.Leu474Ser or p.Thr854Ala) (data not shown). To examine whether the erlotinibresistant tumors harbored increased expression of either known or potentially novel drivers of resistance, we conducted microarray expression profiling of 17 xenograft tumors across each treatment group as well as 2 vehicle-treated control tumors. We asked which genes were differentially regulated in the erlotinib-resistant tumors compared to the control tumors (unpaired t test, P < 0.05). This analysis showed that 21 genes had higher expression (≥1 log 2 fold change) specifically in the erlotinib-resistant tumors ( Supplementary  Table 1 ). Unexpectedly, we found that the receptor tyrosine kinase AXL was the most highly overexpressed gene in the tumors with acquired erlotinib resistance ( Supplementary Table 1 ). In agreement with previous studies 9, 13 , we also observed that MET was among the genes upregulated, although to a much lesser extent than AXL.
We found higher MET mRNA levels (≥1 log 2 fold change) in 5 of 17 (29%) of the tumors with acquired resistance to erlotinib ( Fig. 1b and Supplementary Table 2 ). The analysis did not identify overexpression of IGF1R (encoding insulin-like growth factor 1 receptor), RAS or EGFR in the erlotinib-resistant tumors (Supplementary Tables 1 and 2). Compared to control tumors, expression of AXL was higher (≥1 log 2 fold change) in 15 of 17 (88%) of the tumors with erlotinib resistance ( Fig. 1c and Supplementary Table 2 ). Moreover, we also found higher expression (≥1 log 2 fold change) of GAS6, which encodes the ligand for AXL, in 8 of 17 (47%) of the tumors with erlotinib resistance ( Fig. 1d and Supplementary Table 2 ). AXL was overexpressed in each resistant tumor that had higher MET or GAS6 levels. In 10 of the 15 tumors with AXL upregulation (66.6%), MET overexpression was not observed. In each tumor in which the expression of AXL and MET were both increased, AXL was overexpressed to a higher degree. AXL and GAS6 overexpression was unique to treatment-resistant tumors and was not the result of the acute effects of erlotinib treatment, as expression from these genes was not higher in erlotinib-sensitive tumors harvested after 48 h of erlotinib treatment ( Supplementary Fig. 1 ). Array-comparative genomic hybridization (aCGH) analysis showed that neither AXL nor GAS6 was amplified, and sequencing of AXL revealed that it was not mutated in the erlotinib-resistant tumors (data not shown). On the basis of these findings and recent data showing that AXL can promote cell growth in several cancer cell lines 15, 16 , we hypothesized that AXL overexpression and activation might promote the acquisition of resistance to erlotinib in EGFR-mutant NSCLCs.
AXL has previously been associated with EMT, and recent studies suggest that therapeutic resistance may in some cases be associated with histological changes, including EMT, in NSCLCs 14, 17, 18 . We noted that the tumor xenografts with acquired resistance to erlotinib harbored alterations in the expression of several genes that are npg A r t i c l e s established biomarkers for EMT. For example, we found higher levels of COL6A1 (encoding a type IV collagen), HMGA1 and HMGA2 and lower levels of keratin genes (including KRT6A, KRT14 and KRT5) in the tumors with acquired erlotinib resistance compared with the control tumors ( Supplementary Table 1 ). We further examined whether the erlotinib-resistant xenograft tumors showed molecular changes known to occur during EMT. Indeed, we found downregulation of CDH1 (encoding E-cadherin) (≥0.5 log 2 fold change) in 8 of 15 (53%) ( Fig. 1e and Supplementary Table 2 ), upregulation of COL6A1 (≥1 log 2 fold change) in 14 of 15 (93%) ( Fig. 1f and Supplementary  Table 2 ) and increased VIM (encoding vimentin) (≥1 log 2 fold change) in 10 of 15 (66%) ( Supplementary Fig. 2 ) of the erlotinib-resistant tumors with AXL overexpression compared to the vehicle-treated control tumors.
In agreement with the microarray data, we found higher levels of total and phosphorylated AXL protein in representative resistant HCC827-derived tumor xenografts at each dose of erlotinib compared with vehicle-treated tumors ( Fig. 2a) . We did not find alterations in the levels of total and phosphorylated IGF-1R or Ras in the erlotinib-resistant tumors ( Fig. 2a) . In contrast, we observed lower levels of phosphorylated EGFR, ErbB3 and MET in response to erlotinib treatment, both in erlotinib-sensitive tumors harvested after 48 h of treatment ( Fig. 2b) and in erlotinib-resistant tumors at each dose of erlotinib compared to vehicle-treated tumors ( Fig. 2a) . Erlotinib treatment for 48 h resulted in lower levels of phosphorylated AKT, ERK and RelA and increased Parp cleavage (a marker of apoptosis) in sensitive tumors ( Fig. 2b) , but the levels of phosphorylated AKT, ERK and RelA were maintained in each tumor with acquired resistance to erlotinib ( Fig. 2a) . Furthermore, we observed increased expression of the EMT marker vimentin in several erlotinib-resistant tumors ( Fig. 2a) . These data suggest that AXL upregulation may activate AKT, mitogen-activated protein kinase (MAPK) or NF-κB signaling to promote resistance to erlotinib treatment in EGFR-mutant NSCLCs, perhaps in association with EMT.
AXL inhibition restores erlotinib sensitivity
To determine whether inhibition of AXL could restore erlotinib sensitivity in vivo, we took a genetic approach because the pharmacokinetics and specificity of the currently available AXL inhibitors in vivo are suboptimal. We generated xenograft tumors in immunocompromised mice using either parental HCC827 cells or an erlotinib-resistant subclone of HCC827 cells that we established, which we found to express increased levels of AXL (HCC827 subline ER1). We transduced the AXL-overexpressing HCC827 ER1 cells with either a non-target short hairpin RNA (shRNA) or an shRNA targeting AXL, the resulting cells were engrafted into mice and mice were then treated with either vehicle or erlotinib (12.5 mg/kg/d). As expected, the tumors from parental HCC827 cells were sensitive to erlotinib treatment, whereas the AXL-overexpressing HCC827 ER1 tumors transduced with the non-target shRNA were resistant to erlotinib ( Fig. 2c) . In contrast, knockdown of AXL restored sensitivity to erlotinib in the HCC827 ER1 tumors ( Fig. 2c,d) . The data show that AXL was required for erlotinib resistance in this in vivo model.
To further explore the role of AXL in acquired resistance to EGFR TKIs, we next focused on the new in vitro models of acquired resistance to erlotinib that we generated in conjunction with the in vivo tumor xenograft models. Five erlotinib-resistant HCC827 clonal sublines were established (ER1-ER5) independently in three laboratories, each with erlotinib IC 50 of >10 µM, through prolonged (for >5 months) and continuous exposure to erlotinib ( Fig. 3a) . Each of these cell lines was also resistant to irreversible exposure to the EGFR kinase inhibitor BIBW2992 (afatinib) (Supplementary Fig. 3 ). Thus, resistance in these cellular models is unlikely to arise because the secondary alteration in EGFR (p.Thr790Met) confers drug resistance and is therefore generalizable to distinct classes of EGFR TKIs. Indeed, the EGFR p.Thr790Met resistance-conferring alteration was not detected by sequencing in any ER subline (data not shown). We sought to determine whether AXL or other genes previously implicated in the acquisition of resistance to EGFR TKIs were upregulated in the HCC827 ER1-ER5 sublines compared to parental cells. 
npg
A r t i c l e s
To identify genes that were differentially regulated (threshold of threefold change, false discovery rate (FDR) of <0.1) in the context of acquired resistance to erlotinib, we profiled gene expression in the ER1-ER3 sublines relative to that in parental HCC827 cells using genome-wide microarrays ( Supplementary Table 3 ) and validated our findings by quantitative RT-PCR and protein blots in all five sublines. First, we noted that expression of EGFR, MET, total and phosphorylated IGF-1R and Ras was unaltered in each ER subline ( Fig. 3b) . We did not detect activating mutations in KRAS or BRAF by sequencing of the ER sublines (data not shown). In agreement with our findings in the erlotinib-resistant tumor xenografts, we found substantial upregulation of AXL and its ligand GAS6 in each HCC827 ER subline compared to HCC827 parental cells ( Fig. 3b, Supplementary Fig. 4 and Supplementary Table 3 ). We also found higher expression of vimentin and lower expression of E-cadherin in each ER subline ( Fig. 3b and Supplementary Fig. 4 ). Neither somatic mutations in AXL nor genomic amplification of this gene was found by sequencing and aCGH (or FISH), respectively, in the HCC827 ER sublines (data not shown).
We next asked whether AXL overexpression and activation was necessary for acquired resistance to erlotinib in vitro by genetically or pharmacologically inhibiting AXL in the HCC827 ER sublines. First, we found that knockdown of AXL using a small interfering RNA (siRNA) targeting AXL had no effect on erlotinib sensitivity in parental HCC827 cells but restored erlotinib sensitivity in each ER subline ( Fig. 3c) . Notably, we found that knockdown of GAS6 restored erlotinib sensitivity in the ER1 and ER2 sublines but not in the ER3, ER4 and ER5 sublines (Fig. 3c) . This observation is reminiscent of recent data showing that upregulation of the MET ligand HGF can promote resistance to gefitinib treatment in some EGFR-mutant NSCLC cells 10 . Because we observed residual, albeit diminished, levels of phosphorylated MET in some of the ER sublines, we asked whether MET knockdown by siRNA could restore erlotinib sensitivity in this system. We found that knockdown of MET did not significantly npg A r t i c l e s affect erlotinib sensitivity, either in parental or HCC827 ER1 cells, and did not further enhance the effects of AXL knockdown on erlotinib sensitivity in ER1 cells (Supplementary Fig. 5 ). Treatment with a monoclonal antibody against AXL was recently shown to sensitize NSCLC cell lines that express wild-type EGFR to erlotinib 19 . Thus, we asked whether knockdown of AXL by siRNA could enhance erlotinib sensitivity in five NSCLC cell lines with wildtype EGFR (A549, H460, H1573, H2009 and Calu-1). We found that AXL knockdown had no effect on erlotinib sensitivity in these cell lines (Supplementary Fig. 6 ). Our data suggest that inhibition of AXL enhances erlotinib sensitivity specifically in the context of NSCLCs with activating mutations affecting the kinase domain of EGFR that had acquired resistance to EGFR-targeting TKIs.
Next, we sought to validate our genetic findings using two commercially available small-molecule inhibitors of AXL, MP-470 and XL-880 (ref. 15 ). As expected, treatment with MP-470 (1 µM) or XL-880 (1 µM) alone did not significantly affect the viability of parental HCC827 or ER cells (Supplementary Fig. 7) . In contrast, we found that treatment with MP-470 or XL-880 at the same concentrations restored sensitivity to concurrent erlotinib treatment in each ER subline ( Fig. 3d) . To determine whether treatment with an AXL inhibitor synergized with concurrent erlotinib treatment, we conducted combination index analysis in two of the ER sublines (ER1 and ER4). We found that treatment with either MP-470 or XL-880 but not with the MET inhibitor PHA-665752 was synergistic with concurrent erlotinib treatment (Supplementary Fig. 8) . Taken together, the genetic and pharmacological data show that AXL is required for the acquisition of resistance to erlotinib in this system.
Our aim was then to determine which signaling events downstream of AXL might promote acquired resistance to erlotinib in EGFR-mutant NSCLCs. Because AXL has been shown to activate the MAPK, AKT and NF-κB pathways and to regulate apoptosis in some cancer cell lines 15, 16 , we examined activation of these pathways in parental HCC827 or ER cell lines transfected with a non-target siRNA or with siRNA targeting AXL and treated with either vehicle or erlotinib (100 nM). As expected, we found that erlotinib treatment lowered the levels of phosphorylated ERK, AKT and RelA (a marker of NF-κB signaling) and increased Parp cleavage (a marker of apoptosis) in parental HCC827 cells (Fig. 3e) . The introduction of AXL siRNA had no effect on these pathways in parental HCC827 cells (Fig. 3e) . Erlotinib treatment decreased the levels of phosphorylated EGFR, both in parental HCC827 cells and in the ER1 and ER2 sublines (Fig. 3e) . This observation is consistent with our finding that the ER sublines do not harbor a secondary resistance-conferring mutation in EGFR that would abrogate the ability of erlotinib to inhibit EGFR. In contrast, erlotinib treatment decreased the levels of phosphorylated ERK, AKT and RelA and increased the levels of cleaved Parp only in the context of AXL knockdown in the ER1 and ER2 cell lines (Fig. 3e) . Similar results were observed in the ER3, ER4 and ER5 sublines of HCC827 (Supplementary Fig. 9 ).
We next sought to validate our genetic findings using pharmacological inhibitors of AXL. As expected, erlotinib decreased the levels of phoshorylated EGFR, ERK, AKT and RelA and increased the levels of cleaved Parp in parental HCC827 cells, irrespective of concurrent treatment with MP-470 or XL-880 ( Fig. 3f,g) A r t i c l e s treatment with MP-470 ( Fig. 3f) or XL-880 ( Fig. 3g) in the HCC827 ER1 and ER2 cells. Similar results were observed in the HCC827 ER3, ER4 and ER5 sublines treated with erlotinib and XL-880, either alone or in combination (Supplementary Fig. 9 ). Taken together, these data suggest that AXL activation is necessary for the acquisition of resistance to erlotinib and that the MAPK, AKT and NF-κB pathways may, in part, mediate erlotinib resistance downstream of AXL in this system.
To determine whether AXL is upregulated in the setting of acquired resistance to erlotinib in cells other than HCC827, we used the same erlotinib treatment protocol to establish two isogenic erlotinib-resistant sublines (IC 50 of >1 µM) derived from H3255 cells that express the EGFR p.Leu858Arg mutant commonly found in individuals with lung cancer and that are otherwise sensitive to erlotinib (IC 50 of ~15 nM). As with HCC827 cells, we found (i) overexpression of AXL in the absence of EGFR p.Thr790Met, phosphorylated EGFR and increased levels of phosphorylated MET and (ii) overexpression of the EMT marker VIM (encoding vimentin), and inhibition of AXL by siRNA, MP-470 or XL-880 restored sensitivity to concurrent erlotinib treatment in the H3255 ER sublines (Supplementary Fig. 10) . Taken together, these data show that AXL upregulation promotes the acquisition of resistance to erlotinib in the setting of EMT in EGFR-mutant NSCLC tumor models and that combined inhibition of AXL and EGFR overcomes acquired resistance to erlotinib in these models.
We next asked whether (i) forced expression of AXL is sufficient to induce erlotinib resistance and (ii) whether AXL kinase activity is necessary for the induction of erlotinib resistance by AXL. To address these questions, we generated cDNA constructs that encoded either wild-type AXL or a kinase-impaired mutant of AXL in which a key conserved lysine residue within the kinase domain was changed to arginine (p.Lys567Arg). Transient overexpression of wild-type AXL, but not AXL KD (p.Lys567Arg), in HCC827 cells increased the levels of phosphorylated AXL and the IC 50 for XL-880 (Fig. 3h,i and  Supplementary Fig. 11 ), suggesting that the p.Lys567Arg alteration impairs AXL kinase function. Overexpression of wild-type AXL, but not kinase-impaired AXL KD (p.Lys567Arg), induced resistance to erlotinib in HCC827 cells that was reversed upon treatment with XL-880 (1 µM) (Fig. 3h,i) . In addition, we found that introduction npg A r t i c l e s of wild-type AXL was sufficient to induce partial resistance to erlotinib in PC9 cells that encode EGFR with deletion of exon 19 and are otherwise sensitive to erlotinib (IC 50 of ~25 nM) ( Supplementary  Fig. 12) . Taken together, these data indicate that AXL kinase activity is necessary and sufficient to promote erlotinib resistance in these EGFR-mutant NSCLC models.
To confirm that treatment with an AXL inhibitor restored erlotinib sensitivity via inhibition of AXL and did not occur as a consequence of an off-target effect of drug treatment, we identified the gatekeeper residue within the AXL kinase domain on the basis of structural modeling of the co-crystal structure of MET bound to XL-880 and on the basis of the location of the Thr790 gatekeeper residue in EGFR 20, 21 (Supplementary Fig. 13 ). This analysis indicated that a p.Leu620Met alteration in AXL would be expected to result in a steric clash with XL-880 and would block the ability of XL-880 to inhibit AXL. Thus, we generated a cDNA encoding this gatekeeper mutant of AXL (p.Leu620Met) and introduced it into HCC827 cells to determine whether its expression would block the ability of XL-880 to restore erlotinib sensitivity in the setting of AXL overexpression. Expression of AXL p.Leu620Met significantly increased the IC 50 for XL-880 (Supplementary Fig. 11 ) and blocked the ability of XL-880 to decrease the levels of phosphorylated AXL in HCC827 cells (Fig. 3i) . In contrast to overexpression of wild-type AXL, we found that expression of AXL p.Leu620Met abrogated the ability of XL-880 (1 µM) to restore erlotinib sensitivity in HCC827 cells (Fig. 3h,i) . These data indicate that treatment with the AXL inhibitor XL-880 restores erlotinib sensitivity by inhibiting AXL kinase activation in these EGFR-mutant NSCLC models.
AXL-mediated resistance may occur during EMT
We observed an association between AXL overexpression and markers of EMT, including increased expression of vimentin, in several models of acquired resistance to erlotinib. Recent data indicate that vimentin can promote EMT via epigenetic regulation of genes that are critical for EMT in breast cancer cells 17 . Thus, we sought to determine whether vimentin overexpression was necessary for AXL overexpression and erlotinib resistance in HCC827 cells. We found that knockdown of vimentin with both pooled siRNA and four individual constructs decreased but did not completely abolish AXL expression ( Fig. 4a) . Vimentin knockdown and concomitant downregulation of AXL enhanced erlotinib sensitivity in HCC827 ER3 cells (Fig. 4b) . Because vimentin has been shown to promote migration and adhesion in cells that have undergone EMT 17, 22 , we examined whether HCC827 ER cells showed greater migration and adhesion. We found that HCC827 cells with acquired erlotinib resistance (ER3) show greater migration and adhesion compared to parental HCC827 cells (Fig. 4) . We also found that knockdown of vimentin or AXL or treatment with XL-880 inhibited migration and adhesion of HCC827 ER3 cells but had no effect on parental HCC827 cells (Fig. 4c,d) . Taken together, these data support a possible role for EMT that is marked by vimentin overexpression in the development of acquired resistance to EGFR TKIs that is driven by AXL in this model of human EGFR-mutant lung cancer.
AXL is upregulated in humans with acquired resistance
On the basis of preclinical data, we hypothesized that upregulation of AXL might promote acquired resistance to EGFR TKI treatment in persons with EGFR-mutant NSCLC. To test this hypothesis and to clinically validate our preclinical findings, we measured the expression of AXL by immunohistochemistry (IHC) in 35 matched EGFRmutant NSCLC specimens obtained from affected individuals both before treatment with EGFR TKIs erlotinib or gefitinib and after the development of resistance to these compounds. In cases where enough material was available for additional studies, we also examined specimens for the expression of GAS6 and vimentin (as a marker for EMT) by IHC (scoring system shown in Supplementary Fig. 14) , the presence of the EGFR mutation encoding the p.Thr790Met alteration by sequencing and MET amplification by FISH. All individuals in the cohort we analyzed had either an exon 19 deletion or an exon 21 point mutation (encoding p.Leu858Arg) in EGFR, were treated with either erlotinib or gefitinib and met the established clinical definition of resistance to EGFR TKIs ( Table 2) 23 . The clinical sample set that we analyzed harbored the full spectrum of major alterations known to occur in individuals with EGFR-mutant lung cancer with acquired TKI resistance 9, [12] [13] [14] . Indeed, we detected the EGFR p.Thr790Met alteration in 8 of 28 (29%) and MET amplification in 6 of 31 (19%) of the resistant specimens examined (Fig. 5a,b and Tables 2 and 3) . Compared to the specimens collected before treatment, we detected IHC staining for AXL and GAS6 was scored as shown in supplementary Figure 14 . Vimentin IHC staining was scored using an established, clinically validated protocol 26 . Scale bars, 100 µm in a and 10 µm in b.
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A r t i c l e s higher expression (twofold or greater) of AXL in 7 of 35 (20%), GAS6 in 7 of 28 (25%) and vimentin in 2 of 10 (20%) of the specimens resistant to EGFR TKIs (Fig. 5a,b and Tables 2 and 3) . In three cases (13, 14 and 15) in which AXL was expressed at the same level in the baseline and matched specimen with resistance, we detected increased GAS6 specifically in the resistant specimen (Tables 2 and 3) . This finding is consistent with the hypothesis that GAS6 overexpression may, in some cases, promote AXL activation in the setting of acquired resistance to EGFR TKIs. This hypothesis is supported by our preclinical data showing that knockdown of GAS6 restores erlotinib sensitivity in some ER sublines that also overexpress AXL (Fig. 3c) . In order to provide independent validation of our IHC findings of increased expression of AXL and GAS6, we performed quantitative RT-PCR on a small cohort of EGFR-mutant lung cancer specimens with acquired TKI resistance that were negative for the EGFR p.Thr790Met alteration compared to matched baseline specimens (n = 5). Using stringent cutoffs (threshold of a greater than threefold change in mRNA levels by quantitative RT-PCR), we found increased AXL and GAS6 mRNA levels upon the acquisition of resistance in 20% and 60%, respectively, of these specimens (data not shown). We did not find increased AXL or GAS6 expression in the single specimen in which we detected increased MET expression greater than threefold change in mRNA by quantitative RT-PCR) in this small cohort (data not shown).
Our analysis of the clinical specimens indicates that some EGFRmutant NSCLCs with acquired resistance to EGFR TKIs can harbor multiple mechanisms of resistance. In agreement with previous studies 13 , we detected the EGFR p.Thr790Met alteration in 50% of cases that also harbored MET amplification (Tables 2 and 3) . Furthermore, we found co-occurrence of the EGFR p.Thr790Met alteration and increased AXL and GAS6 expression in a minority of cases (Tables 2  and 3) . In contrast, we did not detect MET amplification in any specimen with TKI resistance that had increased AXL or GAS6 expression (Tables 2 and 3) . Coupled with the preclinical data, our findings suggest that activation of AXL and MET may be mutually exclusive mechanisms of acquired resistance to EGFR TKIs in NSCLC.
DISCUSSION
We have identified activation of the AXL kinase as a new mechanism by which resistance is acquired to EGFR-targeted TKIs in EGFRmutant NSCLCs through an integrated analysis of human EGFRmutant NSCLC tumor models and one of the largest clinical cohorts reported to date of paired EGFR-mutant NSCLC specimens from individuals who acquired resistance to EGFR TKIs. Our analysis of the clinical specimens shows that AXL upregulation is the second most common mechanism by which resistance is acquired to TKIs (after EGFR p.Thr790Met alteration) in EGFR-mutant NSCLCs and has been validated using primary human data. The frequency of the occurrence of the EGFR p.Thr790Met alteration in samples resistant to EGFR TKIs in this cohort is lower than previously reported 9, [12] [13] [14] . Given that the sequencing assay we used to detect the mutation is standard and validated, this discrepancy likely represents either distinct biology of resistance to EGFR TKIs in the setting of AXL or GAS6 upregulation or suggests that there may be greater variability in the frequency of EGFR p.Thre790Met alteration in lung cancers with EGFR TKI resistance than previously described. Notably, we found upregulation of AXL in individuals that developed resistance to both TKIs for EGFR (erlotinib and gefitinib) that are clinically approved for use in NSCLC patients worldwide. Our findings are thus relevant to the vast majority of individuals with EGFR-mutant NSCLC treated with an EGFR TKI.
The data suggest that activation of AXL can occur through its overexpression as well as through upregulation of its ligand GAS6 in the setting of resistance to EGFR-targeted TKIs in EGFR-mutant NSCLCs. This observation is consistent with recent work showing that upregulation of both MET and its ligand HGF can promote resistance to TKIs to EGFR in some EGFR-mutant NSCLCs 10 . Our data showing that in some ER cell lines GAS6 is not required for erlotinib resistance are consistent with earlier work showing that AXL overexpression can promote downstream signaling and induce transformation in the absence of GAS6 expression 24 . Further work will be necessary to fully elucidate the mechanisms by which GAS6 might promote resistance to EGFR TKIs through activation of AXL and whether somatic alterations (amplifications, rearrangements or point mutations) in AXL or GAS6 occur in human EGFR-mutant NSCLCs.
We found that, in some cases, AXL upregulation occurred in the context of what appeared to be EMT and that an EMT-associated transcriptional program involving upregulation of vimentin may, in part, drive AXL overexpression in EGFR-mutant lung cancer cells with acquired resistance to TKIs for EGFR. The data are consistent with previous studies in which vimentin upregulation was associated with AXL overexpression in breast cancer cells 17 . Although other mechanisms of AXL activation likely exist and will need to be investigated, our data are consistent with a model in which AXL mediates the acquisition of resistance to EGFR TKIs in the context of EMT in EGFR-mutant NSCLCs. AXL-overexpressing HCC827 ER cells showed increased migration and adhesion, properties associated with EMT and the metastatic behavior of tumor cells. These findings in EGFR-mutant NSCLC cells with acquired resistance to erlotinib are consistent with previous work showing that overexpression of AXL is associated with increased metastasis and worse prognosis in several cancers 15 . Yet our studies uncover a distinct and specific role for AXL upregulation in acquired resistance to treatment with TKIs targeting EGFR in individuals with EGFR-mutant NSCLC. Our data therefore extend current knowledge of the role of AXL as a general prognostic biomarker in human cancer and show for the first time that AXL is a biomarker of acquired resistance to EGFR-targeted therapy in NSCLC.
Our observation that multiple mechanisms of resistance may contribute to resistance to treatment with EGFR-directed TKIs in individuals with EGFR-mutant NSCLC is consistent with other recent studies 13, 14 . Our data identifying AXL as a mediator of the mechanism of resistance to TKIs for EGFR enhance the understanding of tumor heterogeneity and the molecular mechanisms governing the evolution of resistance to molecularly targeted therapy in individuals with cancer. Further work will be necessary to determine the degree to which AXL activation may cooperate with other genetic and genomic alterations to induce resistance to EGFR inhibitors and other molecularly targeted therapies in lung and other cancers.
Our data show that the kinase activity of AXL is required for erlotinib resistance in EGFR-mutant NSCLC tumor models. This observation provides a strong rationale for the development and testing of AXL npg kinase inhibitors for clinical use in EGFR-mutant NSCLC patients to either prevent or overcome the acquisition of resistance to EGFR TKIs. The preclinical data also suggest that activation of multiple pathways, including MAPK, AKT and NF-κB, may promote resistance to EGFR TKIs downstream of AXL upregulation. This is consistent with previous work showing that AXL can drive the growth of cancer cells through activation of each of these pathways 15, 16, 25 . Further work will be necessary to determine which of these or other signaling pathways is most critical for AXL-driven resistance to EGFR TKIs in EGFR-mutant NSCLC. Such studies may identify additional points for therapeutic intervention in the context of the acquisition of resistance to EGFR TKIs driven by AXL in individuals with EGFR-mutant NSCLC. On the basis of our data, we propose that inhibition of AXL signaling may enhance responses to treatment with EGFR TKIs in appropriately selected EGFR-mutant NSCLC patients.
URLs. Gene Expression Omnibus (GEO), http://www.ncbi.nlm.nih. gov/geo/; Korean Cell Line Bank, http://cellbank.snu.ac.kr/.
METHODS
Methods and any associated references are available in the online version of the paper.
Accession codes. Affymetrix microarray profiling results obtained from the parental and erlotinib-resistant HCC827 samples have been deposited at the Gene Expression Omnibus (GEO) repository under accession GSE38121. Microarray data from the erlotinib-resistant cell line can be found in the GEO database under accession GSE38310.
Note: Supplementary information is available in the online version of the paper.
Sequencing of AXL, EGFR, KRAS and BRAF. Sequencing of the full length of AXL and EGFR was performed with standard methods, using the primers listed in Supplementary Table 5 . Sequencing of exon 2 of KRAS and exons 11 and 15 of BRAF was performed on genomic DNA using validated primers and protocols 13 .
IHC on NSCLC clinical specimens. All specimens were acquired from individuals with NSCLC under the auspices of institutional review board (IRB)approved clinical protocols at each hospital in which informed consent was obtained. Specimens were formalin-fixed, paraffin-embedded (FFPE) tumor tissues that were examined to ensure >75% tumor infiltration. Tissues were stained with hematoxylin and eosin and were assessed by a thoracic pathologist at the Memorial Sloan-Kettering Cancer Center, the Asan Medical Center and the USP Dexeus University Institute. IHC was performed in the Core Research IHC Laboratory at each institution on FFPE sections, as previously described 29 using the following antibodies: human AXL antigen, affinity-purified polyclonal antibody (R&D Systems, AF154AXL); human GAS6, affinitypurified polyclonal antibody (R&D Systems, AB885); human vimentin, affinity-purified polyclonal antibody (Cell Signaling Technology, 3932). Expression was examined by standard IHC using 4-µm thick sections of matched, paired specimens. Deparaffinized tissue sections were stained following the manufacturer's protocol at a dilution of 1:500 on a Ventana Dixcovery XT automated stainer. Vimentin expression was determined by IHC using established methods and clinical scoring criteria 26 .
